NEW YORK (GenomeWeb) – Paradigm today announced a collaboration with Deciphera Pharmaceuticals to predict best responders for Deciphera's kinase inhibitor called altiratinib.
Paradigm will use its PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib in order to determine which patients may be sensitive or resistant to the MET, TIE2, VEGFR2, and TRK (A,B,C) kinase inhibitor.
The phase I study will investigate the use of the drug for MET or TRK genomic alterations in lung cancer, gastric cancer, renal cancer, and glioblastoma multiforme. Altiratinib has been granted orphan drug designation for glioblastoma multiforme by the US Food and Drug Administration.
PCDx is a next-generation sequencing-based cancer test that identifies the underlying genomic and proteomic mutations in a patient's tumor DNA, RNA, and proteins. Earlier this month, Paradigm announced a deal with health insurer Three Rivers Provider Network to cover the test. Last month, preferred provider organization Stratose said it would cover PCDx.